Neuland Laboratories Ltd.

₹19,697

826 (4.4%)

NEULANDLAB Share Price

Pharmaceuticals & Biotechnology

As on July 29, 2026

SectorHealthcare

IndustryPharmaceuticals & Biotechnology

Basic IndustryPharmaceuticals

Market Cap₹ 25,370 Cr

P/E Ratio69.43

Dividend Yield0.02 %

Trendline Performance

We are partnered with TradingView, a global leader in charting and market analysis. Access real-time stock data, explore the powerful Stock Screener , and uncover insights with multiple tools designed for traders.

Unlock Stock of the Month

T&C*

Technicals

Indicators	Value	Signal
5-DMA	18,907.8	Bullish
10-DMA	18,803.4	Bullish
20-DMA	18,944.55	Bullish
50-DMA	17,911.74	Bullish
100-DMA	16,043	Bullish
200-DMA	15,655.85	Bullish

Historical Performance

1 Year

42.3%

3 Years

477.8%

5 Years

891.3%

10 Years

2051.5%

Shareholding Pattern

Values Analysis

Loading chart...

Profit & Loss

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Net Sales	20,230	14,768	15,586	11,912	9,511
Total Expenditure	14,485	11,536	10,960	9,194	8,085
Other Income	302	205	125	97	21
Operating Profit	6,047	3,438	4,751	2,816	1,447
Interest	239	83	140	131	135
Depreciation	917	655	597	528	490
Profit Before Tax	4,890	3,463	4,014	2,157	822
Consolidated Net Profit	3,640	2,601	3,001	1,635	638
Adjusted EPS	284	203	234	127	50

Compounded Sales Growth

10 Years:31.7

5 Years:16.6

3 Years:11.2

TTM:6.5

Compounded Profit Growth

10 Years:67.8

5 Years:35.2

3 Years:17.4

TTM:7

Stock Price CAGR

10 Years:35.9

5 Years:58.2

3 Years:79.4

TTM:41.6

Return on Equity

10 Years:52.7

5 Years:49.7

3 Years:233.9

last year:283.7

Quarterly Results

Below figures are in Rs. Crores

Particulars	Sep-2024	Dec-2024	Mar-2025	Jul-2025	Sep-2025
Sales	1,70,754	1,35,936	1,28,552	1,22,189	1,05,161
Expenses	63,042	56,557	52,457	45,459	34,856
Operating Profit	1,07,712	79,379	76,096	76,730	70,304
OPM %	63%	58%	59%	63%	67%
Other Income	33,912	31,759	27,333	24,879	18,947
Interest	77,780	58,584	59,248	62,137	53,713
Depreciation	2,345	1,681	1,385	1,277	1,221
Profit Before Tax	61,498	50,873	42,796	38,195	34,318
Tax %	25%	25%	26%	29%	35%
Net Profit	46,149	38,151	31,857	27,296	22,446
EPS in Rs	83	69	58	50	42

Balance Sheet

Below figures are in Rs. Crores

Particulars	Mar-2026	Mar-2025	Mar-2024	Mar-2023	Mar-2022
Share Capital	129	129	129	129	129
Total Reserves	18,616	15,119	12,698	9,812	8,276
Long-Term Borrowings	---	---	---	---	---
Total Non-Current Liabilities	3,455	1,894	1,222	1,467	1,798
Other Current Liabilities	4,206	2,113	2,340	2,449	1,523
Short Term Borrowings	---	---	---	112	922
Total Liabilities	29,301	21,799	18,326	15,798	13,835
Capital Work in Progress	2,095	446	459	406	205
Long Term Loans & Advances	574	360	405	202	144
Currents Investments	---	1,077	---	---	34
Short Term Loans and Advances	520	518	620	471	460
Total Current Assets	14,831	11,395	9,211	7,609	5,808
Total Assets	29,301	21,799	18,326	15,798	13,835
Adjusted Book Value	1,460	1,188	999	774	654

Positive

(80 to 100)

Neutral

(60 to 79)

Negative

(0 to 59)

The stock has a high PE of 69.43, indicating expensive valuation or elevated growth expectations.
Over the last three years, the stock delivered a strong 3-year price CAGR of 78.3%, indicating sustained price appreciation.
The stock carries a beta of 0.9, indicating volatility broadly in line with the market.
In the last financial year, the company reported an EBITDA of ₹6047 million, reflecting positive operating performance.
In the previous financial year, the company generated revenue of ₹20230 million, indicating a large and established business.

Investment Calculator

Investment Amount:₹

Investment Amount: ₹ 1000000

Current Value: ₹ 1415624.6

No. of Shares: 72 (Approx)

Performance:41.6%

415624.6

NIFTY Performance: -2.4%

1 day Top Gainers